| Bioactivity | IR-Crizotinib is a NF-κB-inducing kinase (NIK) inhibitor that crosses the blood-brain barrier and fluorescently localizes intracranial glioblastoma (GBM) in mice (IC50=3.381 μM). IR-Crizotinib is conjugated from the near-infrared dye IR-786 and the NF-κB-inducing kinase (NIK) inhibitor Crizotinib. IR-Crizotinib can effectively inhibit the growth and invasion of glioma in vitro and in vivo and can be used in cancer research[1]. |
| Target | IC50: NF-κB-inducing kinase (3.381 μM). |
| Name | IR-Crizotinib |
| CAS | 2387927-74-2 |
| Formula | C53H57Cl2FIN7O |
| Molar Mass | 1024.87 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Pflug KM, et al. Cyanine Dye Conjugation Enhances Crizotinib Localization to Intracranial Tumors, Attenuating NF-κB-Inducing Kinase Activity and Glioma Progression. Mol Pharm. 2023 Nov 8. |
IR-Crizotinib
CAS: 2387927-74-2 F: C53H57Cl2FIN7O W: 1024.87
IR-Crizotinib is a NF-κB-inducing kinase (NIK) inhibitor that crosses the blood-brain barrier and fluorescently localiz
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.